The association between birthweight and perinatal mortality risk in gestational diabetes pregnancies: A retrospective cohort study
This retrospective cohort study of over 92,000 Australian gestational diabetes pregnancies reveals that perinatal mortality risk is lowest for babies in the 75th to 90th birthweight percentiles and increases significantly for those below the 25th percentile, suggesting that current medical practices aimed at restricting fetal growth may inadvertently elevate mortality risks.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In the delicate world of pregnancy, doctors and scientists have long searched for a simple rule to predict which babies are most likely to survive and thrive. For decades, the general consensus has been that a baby's size matters deeply. In the broader population of all pregnancies, the risk of a baby dying before or shortly after birth is lowest when the infant is neither too small nor too large, but sits comfortably in the upper-middle range of growth. When a baby is significantly smaller than average, the risk rises sharply. This pattern has led to a widespread medical belief that for mothers with gestational diabetes—a condition where blood sugar rises during pregnancy—the primary goal should be to stop the baby from growing too large. The logic is that large babies face complications during birth, so medical teams often use diet and medication to gently restrain their growth, hoping to keep them in a "safe" size range.
However, a new study from Australia challenges whether this strategy is actually helping the babies it is meant to protect. Researchers asked a straightforward question: in pregnancies complicated by gestational diabetes, does the same relationship between size and survival hold true? Specifically, they wanted to know if the babies who are growing the most are actually the safest, or if the current medical push to limit their growth might be doing more harm than good. The study looked at nearly 93,000 singleton births in Queensland between 2010 and 2023, tracking every baby born to a mother with gestational diabetes. By comparing the size of each baby at birth against whether that baby survived the pregnancy and the first month of life, the team mapped out the true landscape of risk for these specific pregnancies.
The results painted a clear and somewhat surprising picture. The data showed that the lowest risk of death for these babies occurred when they were born in the 75th to 90th percentile of growth. This means the safest babies were those who were larger than three-quarters of other babies of the same age and sex, but not quite in the very largest group. As the babies' size dropped below this sweet spot, the risk of death climbed steadily. Babies born in the smallest category, below the 10th percentile, faced a risk of death that was nearly eight times higher than those in the safest group. Even babies in the 10th to 25th percentile, who would typically be considered normal-sized, faced a risk of death that was more than double that of the larger, healthier group.
The researchers also looked at the other end of the spectrum. While the risk did rise slightly for the very largest babies, those above the 97th percentile, the danger was far less severe than for the small babies. The study carefully adjusted for many factors that could skew the results, such as the mother's age, weight, and whether the baby had any birth defects. They even tested different scenarios regarding the time between a baby's death and the delivery of the placenta, a factor that can sometimes make small babies look riskier than they are. In every scenario, the pattern remained the same: larger babies within this group were safer than smaller ones.
This finding strikes at the heart of current medical practice. The standard approach to managing gestational diabetes often involves dietary changes and, in many cases, medication to slow down the baby's growth. The goal is to prevent the baby from becoming too large. Yet, this study suggests that for the vast majority of these pregnancies, the babies who are growing the most are actually the ones with the best chance of survival. The authors point out that while we know treatment reduces growth, there is no solid evidence that this reduction improves the baby's health or survival. In fact, by trying to shrink a baby that is naturally growing well, doctors might be inadvertently pushing a healthy baby into a size range where the risk of death is significantly higher.
The study does not claim to prove that the treatment itself causes the deaths, but it highlights a troubling gap in our understanding. The authors argue that if a treatment is designed to shrink a baby, and shrinking a baby is linked to a higher risk of death, then the practice deserves a serious re-evaluation. They suggest that the medical community should pause and debate whether the current habit of pharmacologically restricting growth is safe, especially when the evidence shows that the largest babies in this group are the most robust. The message is not that large babies are always perfect, but that the current fear of size may be causing doctors to overlook the greater danger of smallness. For the mothers and babies involved, the data suggests that a baby growing toward the upper end of the normal range is likely the safest path forward.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.